(Q38993736)

8 September 2017

1 reference

title

Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside (English)

1 reference

8 September 2017

Eva Hornig

1

1 reference

8 September 2017

Markus V Heppt

2

1 reference

8 September 2017

Saskia A Graf

3

1 reference

8 September 2017

Thomas Ruzicka

4

1 reference

8 September 2017

Carola Berking

5

1 reference

8 September 2017

publication date

1 November 2016

1 reference

8 September 2017

published in

Experimental Dermatology

1 reference

8 September 2017

volume

25

1 reference

8 September 2017

issue

11

1 reference

8 September 2017

page(s)

831-838

1 reference

The functional role of long non-coding RNAs and epigenetics

8 September 2017

cites work

1 reference

Melanoma epigenetics: novel mechanisms, markers, and medicines.

21 January 2018

1 reference

Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

21 January 2018

1 reference

Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease.

21 January 2018

1 reference

Histone deacetylases: structural determinants of inhibitor selectivity

21 January 2018

1 reference

HDAC expression and clinical prognosis in human malignancies

21 January 2018

1 reference

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

The role of histone deacetylases (HDACs) in human cancer

21 January 2018

1 reference

Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription

21 January 2018

1 reference

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

Histone deacetylase 1 and 2 regulate Wnt and p53 pathways in the ureteric bud epithelium

21 January 2018

1 reference

Multiple roles of class I HDACs in proliferation, differentiation, and development

21 January 2018

1 reference

Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2.

21 January 2018

1 reference

Histone deacetylases and cancer.

21 January 2018

1 reference

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

The Dual Role of Sirtuins in Cancer

21 January 2018

1 reference

Developmental expression of histone deacetylase 11 in the murine brain

21 January 2018

1 reference

Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function

21 January 2018

1 reference

Expression profile of histone deacetylase 1 in gastric cancer tissues.

21 January 2018

1 reference

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

21 January 2018

1 reference

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

Chromatin-remodelling mechanisms in cancer.

21 January 2018

1 reference

Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy

21 January 2018

1 reference

Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF.

21 January 2018

1 reference

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

21 January 2018

1 reference

Epigenetic regulation in human melanoma: past and future

21 January 2018

1 reference

Epigenetic biomarkers in skin cancer

21 January 2018

1 reference

A rapid micro chromatin immunoprecipitation assay (microChIP).

21 January 2018

1 reference

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma

21 January 2018

1 reference

Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma

21 January 2018

1 reference

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.

21 January 2018

1 reference

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

21 January 2018

1 reference

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

21 January 2018

1 reference

The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.

21 January 2018

1 reference

Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.

21 January 2018

1 reference

Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells

21 January 2018

1 reference

Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis.

21 January 2018

1 reference

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

21 January 2018

1 reference

Selenium-containing histone deacetylase inhibitors for melanoma management

21 January 2018

1 reference

Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.

21 January 2018

1 reference

Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors.

21 January 2018

1 reference

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

21 January 2018

1 reference

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

21 January 2018

1 reference

Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy

21 January 2018

1 reference

The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

Selective Histone Deacetylase Inhibitors

21 January 2018

1 reference

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

21 January 2018

1 reference

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

21 January 2018

1 reference

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors

21 January 2018

1 reference

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

21 January 2018

1 reference

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

21 January 2018

1 reference

Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial

21 January 2018

1 reference

A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

21 January 2018

1 reference

A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

21 January 2018

1 reference

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).

21 January 2018

1 reference

HDAC family: What are the cancer relevant targets?

21 January 2018

1 reference

Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EXD.13089

1 reference

8 September 2017

1 reference